Global Bioinformatics Market to Reach USD 32,663.77 Million by 2031 | CAGR of 10.2%
Category : Pharmaceuticals | Published Date : Nov 2024 | Type : Press Release
Bioinformatics Market Scope & Overview:
As per the Consegic Business Intelligence newly published report, the Bioinformatics Market size was valued at USD 15,135.48 million in 2023, projected to grow at a CAGR of 10.2% during the forecast period to reach USD 32,663.77 million by 2031. Bioinformatics integrates biology, computer science, mathematics, chemistry, and statistics to analyze and interpret complex biological data. It offers tools, software, and platforms to support applications such as genomic sequencing, proteomics, metabolomics, drug discovery, and precision medicine. The field is integral to advancing research and diagnostics, enabling insights into genetic variations, protein functions, and metabolic pathways.
The report comprises the Bioinformatics Market Share, Size & Industry Analysis, based on Component (Bioinformatics Platforms, Bioinformatics Services, Bioinformatics Tools & Software), Application (Genomics, Proteomics, Metabolomics, Pharmacology, Others), End-User (Research Institutions, Pharmaceutical & Biotechnology Companies, Healthcare Organizations, Others), and Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2024-2031.
The report contains detailed information on Bioinformatics Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profiles, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
The rising adoption of next-generation sequencing (NGS), advancements in proteomics, and increasing integration of artificial intelligence (AI) and machine learning (ML) in bioinformatics are key drivers propelling market growth.
Segmental Analysis :
Based on component, the market is bifurcated into Bioinformatics Platforms and Bioinformatics Tools & Software.
- Bioinformatics Platforms: Accounted for the largest market share of 39.74% in 2023, driven by their ability to integrate tools and analytics for genomics, proteomics, and metabolomics research. The shift toward cloud-native architectures further boosts their adoption in large-scale projects.
- Bioinformatics Tools & Software: Expected to grow at the fastest CAGR, fueled by advancements in sequence analysis tools for genome assembly, annotation, and variant calling, alongside AI-driven analytics.
Based on application, the market is bifurcated into Genomics and Drug Discovery and Development.
- Genomics: Held the largest market share in 2023, driven by the widespread use of bioinformatics tools in genome sequencing, annotation, and transcriptomics. Collaborative efforts such as Arima Genomics and Basepair further simplify 3D genomics data analysis.
- Drug Discovery and Development: Anticipated to grow at the fastest rate, supported by bioinformatics' ability to identify molecular targets, optimize drug candidates, and predict pharmacokinetics.
Based on end-user, the market is bifurcated into Pharmaceutical & Biotechnology Companies and Research Institutions.
- Pharmaceutical & Biotechnology Companies: Accounted for the largest share in 2023, attributed to the integration of bioinformatics in drug discovery, precision oncology, and biomarker development.
- Research Institutions: Expected to grow rapidly due to increasing government funding for scientific studies and the rising adoption of bioinformatics in academic research.
Based on region, the market is bifurcated into North America and Asia-Pacific.
- North America: Dominated the market in 2023 with a 41.23% share, valued at USD 6,240.36 million, driven by strong research funding and advancements in genomic technologies. The U.S. leads within the region, accounting for 71.23% of the market.
- Asia-Pacific: Forecasted to grow at the fastest CAGR of 10.9%, propelled by investments in healthcare research, precision medicine, and agricultural biotechnology in China, India, and Japan.
| Report Attributes | Report Details |
| Study Timeline | 2018-2031 |
| Market Size in 2031 | USD 32,663.77 Million |
| CAGR (2024-2031) | 10.2% |
| Component | Bioinformatics Platforms, Bioinformatics Services, Bioinformatics Tools & Software |
| Application | Genomics, Proteomics, Metabolomics, Pharmacology, Others |
| End-User | Research Institutions, Pharmaceutical & Biotechnology Companies, Healthcare Organizations, Others |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The bioinformatics market is highly competitive, with key players focusing on product innovation, strategic collaborations, and leveraging AI and ML technologies to enhance their solutions. This report includes profiles of prominent players, market share analysis, and strategic developments. Major players such as Illumina, Inc. and Thermo Fisher Scientific lead with strong portfolios, while emerging firms like Bioinformatics Solutions Inc. are driving innovation in niche areas like proteomics.
List of prominent players in the Bioinformatics Industry:
- Illumina, Inc. (United States)
- QIAGEN (Netherlands)
- Agilent Technologies, Inc. (United States)
- Waters Corporation (United States)
- Metabolon, Inc. (United States)
- Thermo Fisher Scientific Inc. (United States)
- GenScript (United States)
- Bioinformatics Solutions Inc. (Canada)
- DNAnexus, Inc. (United States)
- BioBam (Spain)
Recent Industry Developments :
- October 2024: SCIEX and Bioinformatics Solutions Inc. co-developed PEAKS 12.5 software, enhancing proteomics analysis compatibility with the ZenoTOF 7600+ system.
- February 2024: Metabolon launched a bioinformatics platform with advanced features like Biomarker Lenses™ for metabolomics research.
- February 2024: QIAGEN unveiled Biomedical KB-AI, a generative AI-driven knowledge base, accelerating data-driven drug discovery.
- July 2023: FOXO Technologies launched Bioinformatics Services to advance research in epigenetics and healthcare.
